Drug Trial Radar · NCT07028320
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture Risk
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
493
Actual
Start
Dec 3, 2021
Primary completion
Dec 30, 2023
Study completion May 20, 2024
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 45 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women with Osteoporosis at High Fracture Risk
Conditions
- Postmenopausal Women With Osteoporosis
Interventions
SAL056 (56.5μg)Drug
Administered by subcutaneous injection once a week during treatment phase
AlendronateDrug
70 mg tablet taken once a week during treatment phase
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in Bone Mineral Density (BMD) of Lumbar Spine from Baseline to 48 WeeksTime frame: Baseline to 48 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Sixth People's Hosptital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.